NIH announces new co-chairs of Panel on Antiretroviral Guidelines
The National Institutes of Health recently announced several changes in leadership on the Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. The panel, a working group of the NIH Office of AIDS Research Advisory Committee (OARAC), consists of approximately 40 representatives from NIH, the Centers for Disease Control and Prevention, the Food and Drug Administration, and the Health Resources and Services Administration, as well as scientists and clinicians from academia and primary care medical practices, and HIV/AIDS community representatives. The panel is charged with regularly updating HIV treatment guidelines based on advances in HIV therapy. The guidelines serve as the standard of medical care for treating HIV-infected patients in the United States.
The following panel leadership changes were announced at a recent OARAC meeting:
John G. Bartlett, M.D., will retire from his position as panel co-chair at the end of 2013, a position he has held since the panel’s creation in 1996.
“Dr. Bartlett was instrumental in the development of the Panel on Antiretroviral Guidelines for Adults and Adolescents and in that capacity, helped to establish the nation’s first HIV treatment guidelines,” said Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH. “His leadership has been highly valued, and he will be sorely missed.” Dr. Fauci served as panel co-chair with Dr. Bartlett from 1996 to 2004.
Dr. Bartlett is professor emeritus of medicine in the Division of Infectious Diseases at The Johns Hopkins University School of Medicine in Baltimore. He served as chief of the Infectious Diseases Division for 26 years before stepping down in 1996. He is a member of the Institute of Medicine, a master of the American College of Physicians, and past president of the Infectious Diseases Society of America.
Roy M. Gulick, M.D., M.P.H., has been named as one of two new panel co-chairs. Currently a professor of medicine and chief of the Division of Infectious Diseases at Weill Medical College of Cornell University in New York City, Dr. Gulick served as a panel member from 2002 to March 2013. In that capacity, he led efforts to revise recommendations on initial antiretroviral treatment regimens and the management of treatment-experienced patients. An expert on antiretroviral treatment strategies, new antiretroviral agents, clinical trial design and clinical management of HIV infection, Dr. Gulick currently serves as principal investigator of the Cornell HIV Clinical Trials Unit, part of the NIH-funded AIDS Clinical Trials Group (ACTG). Additionally, he is co-chair of the Forum for Collaborative HIV Research, a board member of the International AIDS Society-USA, and a member of the American Society of Clinical Investigation. Dr. Gulick served as chairman of the FDA Antiviral Drugs Advisory Committee from 2001 to 2004.
Martin S. Hirsch, M.D., has been named as the second new panel co-chair. Dr. Hirsch currently is a professor of medicine at Harvard Medical School, professor of Immunology and Infectious Diseases at the Harvard School of Public Health, and a physician at Massachusetts General Hospital — all in Boston. Serving on the panel from 1996 to 2012, Dr. Hirsch contributed to guidelines on managing drug resistance and other topics. Dr. Hirsch saw his first AIDS patient in 1981, and has worked on the pathogenesis and therapy of HIV infections for more than 30 years. His laboratory was the first to demonstrate that certain combinations of antiretrovirals had synergistic anti-HIV activity and was central to bringing these findings into large-scale human clinical trials performed within the ACTG. Dr. Hirsch was the first chair of the ACTG and served as director of the Harvard AIDS Clinical Trials Unit from 1986 to 2003. In addition to his current positions, Dr. Hirsch is also editor-in-chief of the Journal of Infectious Diseases.
“Throughout their careers, Drs. Gulick and Hirsch have made substantial contributions to the knowledge base underpinning HIV treatment guidelines,” said Jack Whitescarver, Ph.D., NIH Office of AIDS Research director. “Through their leadership, the Panel on Antiretroviral Guidelines for Adults and Adolescents will continue to set the tone for HIV treatment in the United States.” Dr. Whitescarver, in consultation with Dr. Fauci, selected the new co-chairs.
Both Drs. Gulick and Hirsch are replacing outgoing co-chair Dr. Bartlett and will work alongside the third co-chair H. Clifford Lane, M.D., NIAID’s Clinical Director. Dr. Lane has served as a panel co-chair since 2004.
For more information on OARAC, visit: http://www.oar.nih.gov/oarac.
The NIH Office of AIDS Research (OAR), part of the Office of the Director, plans and coordinates the scientific, budgetary, legislative, and policy elements of the NIH AIDS research program. Additional information, including the trans-NIH strategic plan and budget, is available at http://www.oar.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.